UroGen Pharma Ltd. (URGN) Stock Price & How to Invest

UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on with an NDA targeted for the third quarter of 2026), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus heading into Phase 1. The company had 291 employees as of its latest disclosure and is run by CEO Liz Barrett.

The investment picture changed shape over the past year. Second-quarter 2026 revenue was ~$72.5M against ~$24.2M a year earlier, with Zusduri contributing ~$50.4M and growing ~73% sequentially, and the company posted its first positive quarterly operating income (~$0.1M) even while raising full-year operating expense guidance to ~$260M to $270M to push harder behind the launch. Gross margin runs near 91%, which is what makes the operating leverage credible if the ramp holds. The balance sheet is the counterweight: ~$108M of cash and marketable securities against ~$189M of long-term debt and a ~$125M prepaid forward obligation owed to RTW on future product sales, leaving a shareholders' deficit of ~$132M. At roughly $47 a share and a ~$2.3B market cap, the stock has nearly tripled off its October 2025 low, so what is being priced is Zusduri becoming a large franchise, not what it has already sold.

The company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year. About $42.4M of at-the-market equity capacity remained at June 30, 2026, so dilution is an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now the majority of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and the stock is priced for it not to. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent allowance running to 2044 has to hold up to be worth what the market is assigning it.

8 analysts publish price targets on URGN, averaging $60.00 against a $46.80 price as of August 2026, or +28.2%. The published targets run from $48.00 to $75.00, a moderate spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 7 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full URGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on UroGen Pharma Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Zusduri launch curve. Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second, and the underlying adoption metrics moved with it: 1,444 activated sites of care, 452 unique prescribers, and 204 repeat prescribers, or about 45% of prescribers, up from 40% a quarter earlier. The most optimistic published target, $75.00, assumes this works close to its best case.

The case against. The company still runs a shareholders' deficit of ~$132M with ~$108M of liquidity against ~$189M of term debt and a ~$125M prepaid forward obligation, and its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year. The most pessimistic target, $48.00, is roughly what URGN is worth if this bites instead.

Read the full bull and bear case on URGN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see UroGen Pharma Ltd.'s investor relations page or your broker.

• Market cap: ~$2.3B (~$47 per share, ~48.9M shares)
• Revenue (TTM): ~$189M
• Revenue (Q2 2026): ~$72.5M, vs ~$24.2M a year earlier
• Net loss (Q2 2026): ~$14.4M, or ~$0.28 per share
• Cash & marketable securities: ~$108M
• Long-term debt & prepaid forward obligation: ~$189M and ~$125M

There is no meaningful P/E because UroGen is still loss-making on a trailing basis, roughly ~$98M of net loss over the last twelve months, so the shares are usually framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$2.3B of market value against ~$189M of trailing revenue is roughly 12x sales, but annualising the June quarter at ~$290M brings it closer to 8x, and the two numbers are far apart precisely because the product launched in mid-2025. Adding net debt of roughly $206M pushes enterprise value near ~$2.5B, so the balance sheet is not a rounding error here the way it is for a cash-rich clinical-stage biotech.

Other names that sit close to URGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get URGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so URGN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where URGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

UroGen has crossed from clinical-stage biotech into a real commercial franchise, but at roughly $2.3B of market value against ~$189M of trailing revenue and a shareholders' deficit, the valuation is underwriting several more quarters of Zusduri growth rather than the current run rate.

Whether URGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is URGN a buy or a sell?, and where the stock could go from here in the URGN stock forecast.

For income investors, whether URGN pays a dividend and how the payout looks is covered in does URGN pay a dividend? And to weigh URGN against a peer, read the full side-by-side comparisons: URGN vs JNJ and URGN vs IBRX.